NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/29/2026 12:45
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3.94 mln
Float2.43 mln
Earnings Date08/19/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.81
Caution advised
Relative Strength
53
/ 100
Slightly ahead
Debt / Equity
0.03
Debt-free
ROE
-197
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
60 Degrees Pharmaceuticals is a Washington, D.C.-based company focused on developing and selling treatments for infectious diseases. Its main product, Arakoda, is an approved therapy for malaria prevention, while its pipeline includes tafenoquine, which is being studied for conditions such as COVID-19, babesiosis, and fungal infections, as well as celgosivir for dengue and Zika. The company works with Tufts Medical Center under a licensing agreement to advance tafenoquine for babesiosis treatment and prevention.
